Earnings Insight and Analysis - Express Scripts Holding

LONDON, September 9, 2014 /PRNewswire/ --

Investor-Edge.com has issued free post-earnings insight and analysis on Express Scripts Holding Company (NASDAQ: ESRX). The company reported financial results on July 29, 2014 for Q2 FY14 ended June 30, 2014. Excluding UnitedHealth Group (UNH), Express Scripts Holding's non-GAAP net income and non-GAAP EPS grew 6% and 15%, respectively on a Y-o-Y basis. Our free coverage report can be accessed at:

http://www.investor-edge.com/register

Earnings Overview  

During Q2 FY14, Express Scripts Holding reported net revenue of $25,111 million, compared to $26,382 million in the previous year quarter. The reported quarter revenues exceeded Bloomberg analysts expectations of $24,412 million. Express Scripts Holding's net income attributable to its shareholders narrowed to $515.2 million, or $0.67 per diluted share in Q2 FY14, from $543.0 million, or $0.66 per diluted share in Q2 FY13. Analysts from Bloomberg were expecting the company to report net income of $610.4 million, or $0.82 per diluted share in Q2 FY14. Further, during Q2 FY14, the company's adjusted claims from continuing operations decreased to 324.5, representing a decline of 5% excluding UNH, and a decline of 12% including UNH, from the previous year quarter. The free research on ESRX can be downloaded as in PDF format at:

http://www.Investor-Edge.com/ESRXFreeReport

George Paz, Chairman, and CEO of Express Scripts Holding Co., stated that the company is well positioned to serve its clients with scale, alignment and innovative solutions to lower costs, manage trend and to improve the health outcomes of its members.  He added that, the company is using its scale in formulary management, regulatory compliance and personalized care through its Therapeutic Resource Centers, to control cost and provide a safe, convenient pharmacy experience.  Mr. Paz concluded that Express Scripts' focus on reducing patients' costs while improving their health outcomes, together with its business model, aligns the company's objectives with those of its clients.

For Q3 FY14, Express Scripts Holding is expecting adjusted EPS to be in the range of approximately $1.27 to $1.31, reflecting a Y-o-Y growth of 22% to 26%, excluding UNH, and Y-o-Y growth of 18% to 21%, including UNH. The company's adjusted claims from continuing operations for Q3 FY14 are projected in the range of 315 to 335. For full year FY14, the company narrowed its adjusted EPS guidance from a range of $4.82 to $4.94 to a range of $4.84 to $4.92. The new guidance range indicates a Y-o-Y growth of 17% to 19% excluding UNH and Y-o-Y growth of 12% to 14% including UNH. Sign up and read the free analyst's notes on ESRX at:

http://www.Investor-Edge.com/ESRX-09092014

Stock Performance  

A day after the earnings release, on July 30, 2014, shares in Express Scripts Holding Co. surged 4.95%, and ended the session at $70.61. Over the last one month, the stock has further moved up by 4.79%, and on the last trading session, Monday, September 08, 2014, it closed at $74.82. The stock, on the last close, ended 0.91% lower than its previous day's close, and vacillated between $74.40 and $75.46 during the session. A total of 3.15 million shares were traded, which was below its three months average volume of 4.70 million shares. Over the previous three trading sessions, the company's shares have advanced 1.56%. Moreover, the stock has gained 6.52% from the beginning of 2014. Express Scripts Holding Co.'s shares are trading above their 50-day and 200-day moving averages of $70.41 and $71.38, respectively. Further, the stock traded at a PE ratio of 25.13 and has a Relative Strength Index (RSI) of 67.42. Visit Investor-Edge and access the latest research on ESRX at:

http://www.Investor-Edge.com/ESRXEarningsCoverage

Sneak Peek to Corporate Insider Trading  

In the last one month, Express Scripts Holding Co. has reported corporate insider trading on two dates. On August 25, 2014, Keith Ebling, Executive Vice President & General Counsel at Express Scripts Holding Co., sold 10,000 shares of Express Scripts Holding Co. for $755,000 at a price of $75.50 per share. In addition, on August 28, 2014, Seymour Sternberg, Director at Express Scripts Holding Co. purchased a total of 15,508 of shares, worth $842,079 at an average price of $54.30 per share. On the same day, he sold an equal number of shares for $1,149,390 at $74.12 per share. Complimentary in-depth research on ESRX is available at:

http://www.Investor-Edge.com/ESRXInsiderTrading

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge